Wheeler Lab Members Publications Posters Directions
1. Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, and Verma AK. Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Res 2001; 61, 808.
2. Jansen AP, Dreckschmidt NE, Verwiebe EG, Wheeler DL, Oberley TD, and Verma AK. Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, delta and epsilon transgenic mice. Int J Cancer 2001; 93, 635.
3. Wheeler DL, Reddig PJ, Dreckschmidt NE, and Verma AK. Protein Kinase C Delta-mediated signals to ornithine decarboxylase induction and to suppression of skin tumor promotion is independent. Oncogene 2002; 21:3620.
4. Wheeler DL, Ness KJ, Oberley TD, and Verma AK. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C ε transgenic mice by α-Difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. Cancer Res, Advances in Brief 2003; 63:3037.
5. Wheeler DL, Ness KJ, Oberley TD, and Verma AK. Protein Kinase C epsilon is linked to 12-O-tetradecanoylphorbol-13-acetate-induced Tumor Necrosis Factor alpha ectodomain shedding and to the development of metastatic squamous cell carcinoma in Protein Kinase C epsilon transgenic mice. Cancer Res 2003; 63: 6547.
6. Wheeler DL, Martin KE, Ness KJ, Li Y, Dreckschmidt NE, Wartman M, Ananthaswamy HN, Mitchell DL, and Verma AK. Protein Kinase C ε Is an Endogenous Photosensitizer That Enhances Ultraviolet Radiation-Induced Cutaneous Damage and Development of Squamous Cell Carcinomas. Cancer Res 2004; 64: 7756.
7. Wheeler DL, Ness KJ, Oberley TD, and Verma AK. Overexpression of Protein Kinase C epsilon in the mouse epidermis leads to a spontaneous non-neoplastic myeloproliferative disease. Am J Pathol 2005;166(1) 117-126.
8. Wheeler DL, Li Y, and Verma AK. Development of metastatic squamous cell carcinomas in PKCε transgenic mice is possibly mediated by proinflammatory cytokines in a paracrine mechanism. J Photochem Photobiol 2005; 81:9-18.
9. Li Y, Wheeler DL, Alters W, Chaiswing L, Verma AK and Oberley TD. Early epidermal destruction with subsequent epidermal hyperplasia is a unique feature of the papilloma-independent squamous cell carcinoma phenotype in PKCε overexpressing transgenic mice. Toxicol Pathol 2005; 33: 684-694.
10. Aziz MH, Wheeler DL, Bhamb B and Verma AK. Protein kinase c δ is not a tumor suppressor in ultraviolet radiation-induced development of squamous cell carcinomas: a possible link to specific cytokines and cyclooxygenase-2, Cancer Res 2006; 66:(2), 713.
11. Li Y, Wheeler DL. Ananthaswamy HN, Verma AK, and Oberley TD. Differential Tumor Biology Effects of Double-Initiation in a Mouse Skin Chemical Carcinogenesis Model Comparing Wild Type versus Protein Kinase C epsilon Overexpression Mice, Toxicol Pathol 2007; Vol. 35, No. 7, 942-951.
12. Verma AK, Wheeler DL, Aziz MH and Manoharan H. Review; Protein Kinase Cε is the key mediator of Skin Carcinogenesis, Molecular Carcinogenesis 2008; 45:381–388.
13. Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi, V, Hsu, KT and Harari PM. Mechanisms of Acquired Resistance to Cetuximab: The Role of HER Family Members Oncogene. 2008 Jun 26;27(28):3944-56
14. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Starnes C, Freeman D, and Harari PM. Panitumumab, a Fully Human Anti-EGFR Monoclonal Antibody, Augments Radiation Response in Xenograft Models of Upper Aerodigestive Tract Cancers. Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):534-42
15. Harari PM, Wheeler DL, and Grandis JR. Molecular Target Approaches in Head and Neck Cancer: Epidermal Growth Factor Receptor and Beyond. Semin Radiat Oncol 2008 Jan. 1:19(1); 63-68.
16. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, Harari, PM. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 2009; 15:1585-92.
17. Wheeler DL, Iida, M, Kruser TJ, Ghia AJ, Nechrebecki MM, Armstrong EA, Huang S and Harari PM. Src family Kinases and the Epidermal Growth Factor Receptor Cooperate in Acquired Resistance to Cetuximab. Cancer Biol Ther 2009; 8:696-703.
18. Wheeler DL, Aziz M, and Verma AK. PKC ε is a critical determinant for the development of Squamous Cell Carcinoma. Cancer Res 2008 (in preparation).
19. Li, C, Iida, M, Dunn, EF, Huang, S, Armstrong, EA, Ghia, AJ, Wheeler DL, Nuclear EGFR contributes to acquired resistance to cetuximab. (in press, Oncogene)
20. Dunn, EF, Iida, M, Armstrong, EA, Wheeler DL, Dasatinib re-sensitizes Kras mutant colorectal tumors to cetuximab. (Submitted, Clinical Cancer Research)
21. Kruser, TJ and Wheeler, DL, Mechanisms of Resistance to HER Family Targeting Antibodies (Submitted, Experimental Cell Research)
22. Kruser, TJ, Wheeler, DL, Armstrong, EA, Kozak, KR, Van Der Kogel, AJ, Bussink, J, Coxon, A, Polverino, A, Harari, PH, Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors (Submitted, Int J Radiat Oncol Biol Phys)
23. Li, C, Iida, M, Wheeler, DL, Dasatinib blocks cetuximab and radiation induced nuclear translocation of the epidermal growth factor receptor (Submitted, Clinical Cancer Research)
24. Hatakeyama, H, Wirth, P, Counsell, A, Mardrom, SR, Wood, CB, Gilbert, J, Murphy, B, Yarbrough, W, Wheeler, DL, Harari, PH, Guo, Y, Shyr, Y, Slebos, RJ, Chung, CH, Heparin-binding EGF-like growth factor and its regulator, miR-212, are associated with acquired cetuximab resistance in head and neck squamous cell carcinoma (Submitted, Cancer Research)
Commentaries:
1. Wheeler, DL and Dunn, EF. BB, a novel EGFR small molecule tyrosine kinase inhibitor directed at the EGFR, Commentary. Cancer Biol and Ther (September, 2009)
2. Wheeler DL, Rangnekar VM, and Schwarze SR. Commentary: Anti-ErbB4 antibody therapy combined with radiotherapy in prostate cancer. Cancer Biol Ther. 2008 Jul;7(7):1095-7.
Review Article:
1. Wheeler, DL, Iida, M. & Dunn, E.F. The role of Src in solid tumors. Oncologist 14, 667-78 (2009). 2. Wheeler, DL, Dunn, EF and Harari, PH Understanding resistance to EGFR inhibitors. Nature Review, Clinical Oncology (in press) 3. Kruser, TJ, and Wheeler, DL, Mechanisms of Resistance to HER Family Targeting Antibodies. Experimental cell research, (in press)
Book Chapter:
Wheeler DL, Hoang T and Harari PM. Contribution of Targeted Agents. Functional Preservation and Quality of Life in Head and Neck Radiotherapy - Edited by PM Harari, NP Connor and C Grau, Springer, June 2008.